$212.29
0.72% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
IE0005711209
Symbol
ICLR
Sector
Industry

ICON Plc Stock price

$212.29
-0.55 0.26% 1M
-100.93 32.22% 6M
-70.78 25.00% YTD
-71.88 25.29% 1Y
-95.33 30.99% 3Y
+40.41 23.51% 5Y
+159.93 305.44% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-1.53 0.72%
ISIN
IE0005711209
Symbol
ICLR
Sector
Industry

Key metrics

Market capitalization $17.53b
Enterprise Value $20.41b
P/E (TTM) P/E ratio 23.64
EV/FCF (TTM) EV/FCF 16.62
EV/Sales (TTM) EV/Sales 2.46
P/S ratio (TTM) P/S ratio 2.11
P/B ratio (TTM) P/B ratio 1.79
Revenue growth (TTM) Revenue growth 3.63%
Revenue (TTM) Revenue $8.31b
EBIT (operating result TTM) EBIT $1.14b
Free Cash Flow (TTM) Free Cash Flow $1.23b
Cash position $695.51m
EPS (TTM) EPS $8.98
P/E forward 24.19
P/S forward 2.12
EV/Sales forward 2.47
Short interest 1.62%
Show more

Is ICON Plc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

ICON Plc Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a ICON Plc forecast:

15x Buy
79%
4x Hold
21%

Analyst Opinions

19 Analysts have issued a ICON Plc forecast:

Buy
79%
Hold
21%

Financial data from ICON Plc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
8,307 8,307
4% 4%
100%
- Direct Costs 6,391 6,391
3% 3%
77%
1,916 1,916
7% 7%
23%
- Selling and Administrative Expenses 194 194
9% 9%
2%
- Research and Development Expense - -
-
-
1,722 1,722
7% 7%
21%
- Depreciation and Amortization 579 579
7% 7%
7%
EBIT (Operating Income) EBIT 1,143 1,143
16% 16%
14%
Net Profit 748 748
46% 46%
9%

In millions USD.

Don't miss a Thing! We will send you all news about ICON Plc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ICON Plc Stock News

Neutral
Business Wire
6 days ago
DUBLIN--(BUSINESS WIRE)--ICON plc, (NASDAQ: ICLR) a world-leading healthcare intelligence and clinical research organisation, has been honoured with numerous awards in the second half of 2024. On TIME Magazine's 2024 list of World's Best Companies ICON was ranked as the highest clinical research organisation out of 1,000 companies for the second year in a row, and in its 2025 list of World's Be...
Neutral
Business Wire
11 days ago
DUBLIN--(BUSINESS WIRE)--ICON Announces Appointment of Chief Operating Officer.
Positive
Seeking Alpha
15 days ago
Recent share price weakness is due to temporary headwinds, including client cost-cutting and delays in biotech decision-making, not structural issues in the CRO industry. Long-term prospects remain strong and structural growth drivers are still intact. Short-term headwinds led to attractive valuations, offering a compelling investment opportunity.
More ICON Plc News

Company Profile

ICON plc operates as a clinical research organization, which engages in the provision of outsourced development services to the pharmaceutical, biotechnology, and medical device industries. It specializes in the strategic development, management and analysis of programs that support clinical development. The company was founded by John Climax and Ronan Lambe in June 1990 and is headquartered in Dublin, Ireland.

Head office Ireland
CEO Stephen Cutler
Employees 41,100
Founded 1989
Website www.iconplc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today